Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ajay K. Singh, M.D., M.B.,B.S.

Title
Institution
Department
Address
Phone
Fax
Other Positions
Title
Institution
Department

Mentoring
Assessing knowledge of diabetes among adolescents in central Sri Lanka and exploring ongoing awareness programs
International, 06/20/06 - 08/20/06

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. M01RR002635 (GOTTLIEB, GARY L) Dec 1, 1984 - Mar 31, 2010
    NIH/NCRR
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Surana SP, Pun PH, Keithi-Reddy SR, Spiegel SM, Middleton JP, Singh AK. Sudden cardiac arrest in ESRD patients. Clin Nephrol. 2014 Feb; 81(2):121-31. PMID: 23149247.
    Citations: 1     Fields:    Translation:Humans
  2. Alsuwadia AO, Farag YM, Al Sayyari AA, Mousa DH, Alhejaili FF, Al-Harbi AS, Housawi AA, Mittal BV, Singh AK. Prevalence of vitamin D deficiency in Saudi adults. Saudi Med J. 2013 Aug; 34(8):814-8. PMID: 23974452.
    Citations: 23     Fields:    Translation:Humans
  3. Singh AK. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem. Semin Dial. 2013 Sep-Oct; 26(5):531-4. PMID: 23763643.
    Citations: 1     Fields:    Translation:Humans
  4. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, Ballal HS, P G, Issacs R, Jasuja S, Kirpalani AL, Kher V, Modi GK, Nainan G, Prakash J, Rana DS, Sreedhara R, Sinha DK, V SB, Sunder S, Sharma RK, Seetharam S, Raju TR, Rajapurkar MM. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013 May 28; 14:114. PMID: 23714169; PMCID: PMC3848478.
    Citations: 32     Fields:    Translation:Humans
  5. McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58. PMID: 23735819.
    Citations: 18     Fields:    Translation:Humans
  6. Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013 Mar; 22(2):198-203. PMID: 23340215.
    Citations: 33     Fields:    Translation:Humans
  7. Sarnak MJ, Tighiouart H, Scott TM, Lou KV, Sorensen EP, Giang LM, Drew DA, Shaffi K, Strom JA, Singh AK, Weiner DE. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013 Jan 29; 80(5):471-80. PMID: 23303848; PMCID: PMC3590049.
    Citations: 44     Fields:    Translation:Humans
  8. Farag YM, Kari JA, Singh AK. Chronic kidney disease in the Arab world: a call for action. Nephron Clin Pract. 2012; 121(3-4):c120-3. PMID: 23208083.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  9. Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46. PMID: 23159232.
    Citations: 3     Fields:    Translation:Humans
  10. Singh AK. Anaemia: Does the KDIGO guideline move the needle in CKD anaemia? Nat Rev Nephrol. 2012 Nov; 8(11):616-8. PMID: 23007621.
    Citations: 1     Fields:    Translation:Humans
  11. Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep; 60(3):390-401. PMID: 22537421; PMCID: PMC3408568.
    Citations: 6     Fields:    Translation:Humans
  12. Farag YM, Keithy-Reddy SR, Mittal BV, Bansal V, Fareed J, Singh AK. Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. Clin Appl Thromb Hemost. 2012 Sep; 18(5):453-61. PMID: 22496088.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  13. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi-Reddy SR, McGill JB, McMurray JJ, Singh AK, Solomon SD, Uno H, Pfeffer MA. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8. PMID: 22104547.
    Citations: 21     Fields:    Translation:Humans
  14. Singh AK. Is there a deleterious effect of erythropoietin in end-stage renal disease? Kidney Int. 2011 Sep; 80(6):569-71. PMID: 21878954.
    Citations:    Fields:    Translation:Humans
  15. Singh AK, Racusen LC. ASN clinicopathologic conference. Clin J Am Soc Nephrol. 2011 Nov; 6(11):2722-8. PMID: 21885795.
    Citations:    Fields:    Translation:Humans
  16. Alsuwaida AO, Farag YM, Al Sayyari AA, Mousa D, Alhejaili F, Al-Harbi A, Housawi A, Mittal BV, Singh AK. Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) - a pilot study. Saudi J Kidney Dis Transpl. 2010 Nov; 21(6):1066-72. PMID: 21060175.
    Citations: 14     Fields:    Translation:HumansPHPublic Health
  17. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55. PMID: 20843249.
    Citations: 93     Fields:    Translation:Humans
  18. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):420-4. PMID: 20689425.
    Citations: 14     Fields:    Translation:Humans
  19. Singh AK. Message to the FDA on ESAs: REMS is not enough, more studies are needed. Clin J Am Soc Nephrol. 2010 Aug; 5(8):1355-8. PMID: 20688885.
    Citations:    Fields:    Translation:Humans
  20. Singh AK. Diabetes, anemia and CKD: Why TREAT? Curr Diab Rep. 2010 Aug; 10(4):291-6. PMID: 20544312.
    Citations: 4     Fields:    Translation:Humans
  21. Patel TV, Singh AK. Anemia in chronic kidney disease: new advances. Heart Fail Clin. 2010 Jul; 6(3):347-57. PMID: 20630409.
    Citations: 4     Fields:    Translation:Humans
  22. Agarwal AK, Singh AK. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes. Heart Fail Clin. 2010 Jul; 6(3):323-32. PMID: 20630407.
    Citations: 1     Fields:    Translation:Humans
  23. Singh AK. Even in nephrology, gurudakshina is important. Kidney Int. 2010 Jul; 78(1):3-5. PMID: 20551921.
    Citations:    Fields:    Translation:Humans
  24. Singh AK. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol. 2010; 31(6):552-6; discussion 563-4. PMID: 20501988.
    Citations:    Fields:    Translation:Humans
  25. Singh AK. ESAs in dialysis patients: are you a hedgehog or a fox? J Am Soc Nephrol. 2010 Apr; 21(4):543-6. PMID: 20357173.
    Citations: 3     Fields:    Translation:Humans
  26. Singh AK. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6. PMID: 20203166.
    Citations: 4     Fields:    Translation:HumansCellsPHPublic Health
  27. Singh AK. Should we keep hemoglobin levels as a viable outcome measure? Nephrol News Issues. 2010 Mar; 24(3):15-6, 18. PMID: 20364493.
    Citations: 1     Fields:    Translation:Humans
  28. Singh AK, Nachiappan AC, Verma HA, Uppot RN, Blake MA, Saini S, Boland GW. Postoperative imaging in liver transplantation: what radiologists should know. Radiographics. 2010 Mar; 30(2):339-51. PMID: 20228321.
    Citations: 20     Fields:    Translation:Humans
  29. Ingsathit A, Thakkinstian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, Ongaiyooth L, Vanavanan S, Sirivongs D, Thirakhupt P, Mittal B, Singh AK. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant. 2010 May; 25(5):1567-75. PMID: 20037182.
    Citations: 38     Fields:    Translation:Humans
  30. Singh AK. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol. 2010 Jan; 21(1):2-6. PMID: 20035034.
    Citations: 19     Fields:    Translation:HumansCells
  31. Mittal BV, Singh AK. Hypertension in the developing world: challenges and opportunities. Am J Kidney Dis. 2010 Mar; 55(3):590-8. PMID: 19962803.
    Citations: 45     Fields:    Translation:Humans
  32. Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010 Feb; 77(3):239-46. PMID: 19890274; PMCID: PMC2902281.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  33. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32. PMID: 19880844.
    Citations: 402     Fields:    Translation:Humans
  34. Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis. 2009 Sep; 54(3):498-510. PMID: 19628315.
    Citations: 11     Fields:    Translation:Humans
  35. Singh AK. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol. 2009 Jul; 20(7):1436-41. PMID: 19579295.
    Citations: 4     Fields:    Translation:Humans
  36. Fishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, Wish JB. Posttransplant anemia: the role of sirolimus. Kidney Int. 2009 Aug; 76(4):376-82. PMID: 19553912.
    Citations: 7     Fields:    Translation:Humans
  37. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69. PMID: 19501439.
    Citations: 11     Fields:    Translation:Humans
  38. Alexander MP, Patel TV, Farag YM, Florez A, Rennke HG, Singh AK. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009 May; 53(5):751-9. PMID: 19339092; PMCID: PMC2765403.
    Citations: 17     Fields:    Translation:Humans
  39. Patel TV, Singh AK. Role of vitamin D in chronic kidney disease. Semin Nephrol. 2009 Mar; 29(2):113-21. PMID: 19371802; PMCID: PMC2696155.
    Citations: 11     Fields:    Translation:HumansAnimals
  40. Patel TV, Singh AK. Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions. Semin Nephrol. 2009 Mar; 29(2):105-12. PMID: 19371801; PMCID: PMC2696636.
    Citations: 2     Fields:    Translation:Humans
  41. Singh A. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence. Semin Dial. 2009 Jan-Feb; 22(1):64-9. PMID: 19175537.
    Citations: 3     Fields:    Translation:Humans
  42. Singh AK. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Am J Kidney Dis. 2008 Dec; 52(6 Suppl):S5-13. PMID: 19010260.
    Citations: 8     Fields:    Translation:Humans
  43. Patel TV, Mittal BV, Keithi-Reddy SR, Duffield JS, Singh AK. Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract. 2008; 110(4):c244-50. PMID: 18974656; PMCID: PMC2818376.
    Citations: 7     Fields:    Translation:Humans
  44. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009 Jan; 53(1):26-32. PMID: 18930568.
    Citations: 44     Fields:    Translation:Humans
  45. Pizzi LT, Bunz TJ, Coyne DW, Goldfarb DS, Singh AK. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95. PMID: 19034302.
    Citations: 3     Fields:    Translation:Humans
  46. Patel TV, Singh AK. Does treatment with calcitriol improve survival in predialysis patients with chronic kidney disease? Nat Clin Pract Endocrinol Metab. 2008 Sep; 4(9):484-5. PMID: 18607400.
    Citations: 1     Fields:    
  47. Keithi-Reddy SR, Singh AK. Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol. 2009 Mar; 24(3):431-4. PMID: 18604563.
    Citations: 3     Fields:    Translation:Humans
  48. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 Sep; 74(6):791-8. PMID: 18596733; PMCID: PMC2902279.
    Citations: 111     Fields:    Translation:HumansCTClinical Trials
  49. Rocuts AK, Waikar SS, Alexander MP, Rennke HG, Singh AK. Acute phosphate nephropathy. Kidney Int. 2009 May; 75(9):987-91. PMID: 18580858.
    Citations: 5     Fields:    Translation:Humans
  50. Fishbane S, Singh AK. Iron deficiency in non-dialysis chronic kidney disease. Kidney Int. 2009 Apr; 75(7):752-4. PMID: 18563050.
    Citations: 2     Fields:    Translation:Humans
  51. Alexander MP, Farag YM, Mittal BV, Rennke HG, Tullius SG, Singh AK. De novo multifocal renal cell carcinoma in the renal allograft. Kidney Int. 2009 Jan; 75(1):111-4. PMID: 18563056.
    Citations: 2     Fields:    Translation:Humans
  52. Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 2008 Dec; 74(12):1617-22. PMID: 18547998.
    Citations: 5     Fields:    Translation:Humans
  53. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 Sep; 74(6):782-90. PMID: 18547996; PMCID: PMC2739585.
    Citations: 11     Fields:    Translation:HumansCells
  54. Surana SP, Riella LV, Keithi-Reddy SR, Charytan DM, Singh AK. Acute coronary syndrome in ESRD patients. Kidney Int. 2009 Mar; 75(5):558-62. PMID: 18509314.
    Citations: 3     Fields:    Translation:Humans
  55. Singh AK, Milford E, Fishbane S, Keithi-Reddy SR. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int. 2008 Sep; 74(5):679-83. PMID: 18337717.
    Citations: 7     Fields:    Translation:Humans
  56. Kakkar R, Sobieszczyk P, Binkert CA, Faxon DP, Mortele KJ, Singh AK. Prevention of intravenous contrast-induced nephropathy in hospital inpatients. Crit Pathw Cardiol. 2008 Mar; 7(1):1-4. PMID: 18458660.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  57. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008 Feb; 19(2):372-9. PMID: 18216316; PMCID: PMC2396742.
    Citations: 37     Fields:    Translation:Humans
  58. Singh AK, Fishbane S. The optimal hemoglobin in dialysis patients- a critical review. Semin Dial. 2008 Jan-Feb; 21(1):1-6. PMID: 18251947.
    Citations: 3     Fields:    Translation:Humans
  59. Singh AK. Anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2008 Jan; 3(1):3-6. PMID: 18077779.
    Citations: 3     Fields:    Translation:Humans
  60. Weiner DE, Miskulin DC, Seefeld K, Ladik V, Zager PG, Singh AK, Johnson HK, Meyer KB. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol. 2007 Dec; 18(12):3184-91. PMID: 17978308.
    Citations: 2     Fields:    Translation:Humans
  61. Singh AK. Does correction of anemia slow the progression of chronic kidney disease? Nat Clin Pract Nephrol. 2007 Dec; 3(12):638-9. PMID: 17940523.
    Citations: 2     Fields:    Translation:HumansAnimals
  62. Patel TV, Robinson K, Singh AK. Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues. 2007 Oct; 21(11):57, 59, 63-4 passim. PMID: 17970510.
    Citations: 2     Fields:    Translation:Humans
  63. Singh AK. Anemia of chronic kidney disease: CHOIR and the FDA. Nat Clin Pract Nephrol. 2007 Aug; 3(8):406-7. PMID: 17593919.
    Citations:    Fields:    Translation:Humans
  64. Singh AK. The FDA black box for EPO: what should nephrologists do? Nephrol News Issues. 2007 May; 21(6):55-6, 58-9. PMID: 17518125.
    Citations: 1     Fields:    Translation:Humans
  65. Provenzano R, Singh AK. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract. 2007 May-Jun; 13(3):251-9. PMID: 17599856.
    Citations:    Fields:    Translation:Humans
  66. Sharma R, Tewari KN, Bhatnagar A, Mondal A, Mishra AK, Singh AK, Chopra MK, Rawat H, Kashyap R, Tripathi RP. Tc-99m ciprofloxacin scans for detection of tubercular bone infection. Clin Nucl Med. 2007 May; 32(5):367-70. PMID: 17452864.
    Citations: 7     Fields:    Translation:Humans
  67. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Anaemia of CKD--the CHOIR study revisited. Nephrol Dial Transplant. 2007 Jul; 22(7):1806-10. PMID: 17420166.
    Citations: 1     Fields:    Translation:Humans
  68. Singh AK, Coyne DW, Shapiro W, Rizkala AR. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007 Jun; 71(11):1163-71. PMID: 17396118.
    Citations: 16     Fields:    Translation:Humans
  69. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007 Mar; 18(3):975-84. PMID: 17267740.
    Citations: 81     Fields:    Translation:Humans
  70. Singh AK. The target hemoglobin in patients with chronic kidney disease. Nephrol News Issues. 2006 Dec; 20(13):29-30. PMID: 17168056.
    Citations: 1     Fields:    Translation:Humans
  71. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16; 355(20):2085-98. PMID: 17108343.
    Citations: 502     Fields:    Translation:Humans
  72. Brenner L, Singh AK, Campbell D, Frei F, Winkelmayer WC. Associations between demographic factors and provider structures on cost and length of stay for hemodialysis patients with vascular access failure. Clin J Am Soc Nephrol. 2006 May; 1(3):455-61. PMID: 17699245.
    Citations: 2     Fields:    Translation:Humans
  73. Singh AK, Hertello P. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease. Nephrol Nurs J. 2005 Mar-Apr; 32(2):199-206; quiz 207-8. PMID: 15889804.
    Citations:    Fields:    Translation:Humans
  74. Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar; 149(3):408-13. PMID: 15864229.
    Citations: 21     Fields:    Translation:Humans
  75. Pfeffer MA, Solomon SD, Singh AK, Ivanovich P, McMurray JJ. Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med. 2005; 6 Suppl 3:S35-41. PMID: 16340937.
    Citations:    Fields:    Translation:Humans
  76. Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens. 2005 Jan; 14(1):1-8. PMID: 15586009.
    Citations: 5     Fields:    Translation:Humans
  77. Mittal B, Hurwitz S, Rennke H, Singh AK. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis. 2004 Dec; 44(6):1050-9. PMID: 15558526.
    Citations: 19     Fields:    Translation:Humans
  78. Pendse S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis. 2004 May; 43(5):772-81. PMID: 15112167.
    Citations: 9     Fields:    Translation:HumansCells
  79. Singh AK, Colvin RB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-2003. A 68-year-old woman with impaired renal function. N Engl J Med. 2003 Nov 20; 349(21):2055-63. PMID: 14627791.
    Citations: 5     Fields:    Translation:Humans
  80. Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol. 2003 Oct; 14(10):2573-80. PMID: 14514734.
    Citations: 74     Fields:    Translation:HumansCTClinical Trials
  81. Kewalramani R, Singh AK. Immunopathogenesis of lupus and lupus nephritis: recent insights. Curr Opin Nephrol Hypertens. 2002 May; 11(3):273-7. PMID: 11981256.
    Citations: 3     Fields:    Translation:HumansCells
  82. Singh AK. Immunopathogenesis of the antiphospholipid antibody syndrome: an update. Curr Opin Nephrol Hypertens. 2001 May; 10(3):355-8. PMID: 11342797.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Singh's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (297)
Explore
_
Co-Authors (28)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.